⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for cd20 positive

Every month we try and update this database with for cd20 positive cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study titleNCT IDConditionsInterventionsEligibilityOrganizationLink
Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic LeukemiaNCT04007029
CD19 Positive
CD20 Positive
Recurrent Chron...
Recurrent Diffu...
Recurrent Folli...
Recurrent Mantl...
Recurrent Prima...
Recurrent Small...
Refractory Chro...
Refractory Diff...
Refractory Foll...
Refractory Mant...
Refractory Prim...
Refractory Smal...
Chimeric Antige...
Cyclophosphamid...
Fludarabine Pho...
Tocilizumab
18 Years - 70 YearsJonsson Comprehensive Cancer Center
Ibrutinib and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-cell LymphomaNCT02219737
CD20 Positive
Recurrent Diffu...
Refractory Diff...
Carboplatin
Etoposide
Ibrutinib
Ifosfamide
Laboratory Biom...
Pharmacological...
Rituximab
18 Years - National Cancer Institute (NCI)
Venetoclax and Acalabrutinib in Treating Patients With Relapsed or Refractory Mantle Cell LymphomaNCT03946878
Blastoid Varian...
CCND1 Protein O...
CD20 Positive
CD5 Positive
FCER2 Negative
Pleomorphic Var...
Recurrent Mantl...
Refractory Mant...
t(11;14)(q13;q3...
Acalabrutinib
Venetoclax
18 Years - M.D. Anderson Cancer Center
Ibrutinib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Older Patients With Newly Diagnosed Mantle Cell LymphomaNCT01880567
CCND1 Positive
CCND2 Positive
CCND3 Positive
CD20 Positive
Mantle Cell Lym...
Recurrent Mantl...
Refractory Mant...
Ibrutinib
Laboratory Biom...
Rituximab
18 Years - M.D. Anderson Cancer Center
Ibrutinib in Combination With Rituximab and Lenalidomide in Treating Patients With Previously Untreated, Stage II-IV Follicular Lymphoma or Marginal Zone LymphomaNCT02532257
Ann Arbor Stage...
Ann Arbor Stage...
Ann Arbor Stage...
Ann Arbor Stage...
Ann Arbor Stage...
Ann Arbor Stage...
CD20 Positive
Grade 1 Follicu...
Grade 2 Follicu...
Grade 3a Follic...
Ibrutinib
Laboratory Biom...
Lenalidomide
Rituximab
18 Years - M.D. Anderson Cancer Center
Bortezomib and Chemotherapy in Treating Participants With Lymphoid Malignancies Undergoing Stem Cell TransplantNCT00439556
CD20 Positive
Hematopoietic a...
Lymphocytic Neo...
Lymphoma
Allogeneic Hema...
Anti-Thymocyte ...
Bortezomib
Carmustine
Cytarabine
Etoposide
Filgrastim
Melphalan
Methotrexate
Rituximab
Tacrolimus
- 70 YearsM.D. Anderson Cancer Center
Fludarabine, Bendamustine, and Rituximab in Treating Participants With Lymphoid Cancers Undergoing Stem Cell TransplantNCT00880815
CD20 Positive
Chronic Lymphoc...
Follicular Lymp...
Mantle Cell Lym...
Marginal Zone L...
Recurrent Diffu...
T-Cell Non-Hodg...
Allogeneic Hema...
Anti-Thymocyte ...
Bendamustine
Filgrastim
Fludarabine
Methotrexate
Rituximab
Tacrolimus
18 Years - 70 YearsM.D. Anderson Cancer Center
Ofatumumab in Japanese Patients With CD20 Positive Follicular Lymphoma or Chronic Lymphocytic LeukemiaNCT00742144
Leukaemia, Lymp...
ofatumumab
20 Years - 79 YearsGlaxoSmithKline
Ipilimumab and Rituximab in Treating Patients With Relapsed or Refractory B-cell LymphomaNCT01729806
CD20 Positive
Recurrent B-Cel...
Refractory B-Ce...
Ipilimumab
Laboratory Biom...
Rituximab
18 Years - National Cancer Institute (NCI)
Ipilimumab and Rituximab in Treating Patients With Relapsed or Refractory B-cell LymphomaNCT01729806
CD20 Positive
Recurrent B-Cel...
Refractory B-Ce...
Ipilimumab
Laboratory Biom...
Rituximab
18 Years - National Cancer Institute (NCI)
Ibrutinib and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-cell LymphomaNCT02219737
CD20 Positive
Recurrent Diffu...
Refractory Diff...
Carboplatin
Etoposide
Ibrutinib
Ifosfamide
Laboratory Biom...
Pharmacological...
Rituximab
18 Years - National Cancer Institute (NCI)
Rituximab With or Without Stem Cell Transplant in Treating Patients With Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete RemissionNCT03267433
CD20 Positive
Mantle Cell Lym...
Autologous Hema...
Laboratory Biom...
Rituximab
18 Years - 70 YearsEastern Cooperative Oncology Group
Combination Chemotherapy and Ofatumumab in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic LymphomaNCT01363128
Acute Lymphobla...
Adult Acute Lym...
Burkitt Leukemi...
Burkitt Lymphom...
CD20 Positive
Childhood Acute...
Lymphoblastic L...
Cyclophosphamid...
Cytarabine
Dexamethasone
Doxorubicin Hyd...
Laboratory Biom...
Methotrexate
Ofatumumab
Vincristine Sul...
- M.D. Anderson Cancer Center
Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic LeukemiaNCT04007029
CD19 Positive
CD20 Positive
Recurrent Chron...
Recurrent Diffu...
Recurrent Folli...
Recurrent Mantl...
Recurrent Prima...
Recurrent Small...
Refractory Chro...
Refractory Diff...
Refractory Foll...
Refractory Mant...
Refractory Prim...
Refractory Smal...
Chimeric Antige...
Cyclophosphamid...
Fludarabine Pho...
Tocilizumab
18 Years - 70 YearsJonsson Comprehensive Cancer Center
Ofatumumab in Japanese Patients With CD20 Positive Follicular Lymphoma or Chronic Lymphocytic LeukemiaNCT00742144
Leukaemia, Lymp...
ofatumumab
20 Years - 79 YearsGlaxoSmithKline
Rituximab With or Without Stem Cell Transplant in Treating Patients With Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete RemissionNCT03267433
CD20 Positive
Mantle Cell Lym...
Autologous Hema...
Laboratory Biom...
Rituximab
18 Years - 70 YearsEastern Cooperative Oncology Group
Ibrutinib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Older Patients With Newly Diagnosed Mantle Cell LymphomaNCT01880567
CCND1 Positive
CCND2 Positive
CCND3 Positive
CD20 Positive
Mantle Cell Lym...
Recurrent Mantl...
Refractory Mant...
Ibrutinib
Laboratory Biom...
Rituximab
18 Years - M.D. Anderson Cancer Center
Carfilzomib, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Stage I-IV Diffuse Large B-cell LymphomaNCT01959698
CD20 Positive
Recurrent Diffu...
Refractory Diff...
Stage I Diffuse...
Stage II Diffus...
Stage III Diffu...
Stage IV Diffus...
Carboplatin
Carfilzomib
Etoposide
Ifosfamide
Laboratory Biom...
Pharmacological...
Rituximab
18 Years - 75 YearsRoswell Park Cancer Institute
Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic LeukemiaNCT04007029
CD19 Positive
CD20 Positive
Recurrent Chron...
Recurrent Diffu...
Recurrent Folli...
Recurrent Mantl...
Recurrent Prima...
Recurrent Small...
Refractory Chro...
Refractory Diff...
Refractory Foll...
Refractory Mant...
Refractory Prim...
Refractory Smal...
Chimeric Antige...
Cyclophosphamid...
Fludarabine Pho...
Tocilizumab
18 Years - 70 YearsJonsson Comprehensive Cancer Center
Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: